Volume spike pre-market: H02.SI Haw Par (SES) 21 Mar 2026, watch 8.80% yield

We see a clear pre-market volume spike in H02.SI stock as trading opens in Singapore on 21 Mar 2026. The share price is S$15.39 with 508,300 shares traded versus a 50-day average volume of 317,276. That volume is about +60.20% above average, signalling increased interest ahead of the session. We assess valuation, dividend signals, technicals and short-term catalysts for SES traders.

Pre-market trade data for H02.SI stock

Haw Par Corporation Limited (H02.SI) opened pre-market at S$15.56 with the last regular price at S$15.39. Intraday range so far: S$15.34 to S$15.56. Market capitalisation is SGD 3.52B. Volume of 508,300 versus average 317,276 shows a +60.20% increase. One clear fact: the larger-than-normal volume is concentrated before the Singapore session, which often precedes directional moves in the day session.

Why the volume spike matters for H02.SI stock

A pre-market volume spike often reflects either informed trading or portfolio flows. For H02.SI stock, higher turnover can compress bid-ask spreads and test resistance near the 50-day average S$16.29. Institutional buying would typically lift on-book volume indicators; Haw Par’s OBV sits at 7,076,300, and MFI is 71.55, consistent with buyer-driven activity. Traders should watch whether volume confirms a breakout above S$16.29 or fades back to the 200-day average S$14.78.

Valuation, dividends and fundamentals for H02.SI stock

Haw Par’s trailing EPS is S$1.20 and the price-to-earnings ratio is 13.25, below the Healthcare sector average PE of 21.54, suggesting relative value. The company pays S$1.40 per share in dividends, implying a TTM dividend yield of 8.80%, with a payout ratio near 116.75%. Book value per share is S$19.38 and price-to-book is 0.82, which supports a conservative valuation view for long-term investors.

Technical and sector context for H02.SI stock

Technical readings are mixed: RSI is 51.81, ADX 35.49 (strong trend), and CCI 186.96 (short-term overbought). Bollinger middle band is S$15.65. The healthcare sector on SES has lagged recently, with average PE 21.54, so Haw Par’s lower PE offers relative defensive exposure. Watch support at S$14.19 (BB lower) and resistance near S$17.33 (52-week high).

Meyka AI grade, forecast and analyst view for H02.SI stock

Meyka AI rates H02.SI with a score out of 100: 74.35/100 — Grade B+ (BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly S$14.18, quarterly S$17.30, and yearly S$20.09. Compared with the current price S$15.39, the one-year model implies an ~30.52% upside. Forecasts are model-based projections and not guarantees. For further position data see H02.SI holdings and our internal hub H02.SI on Meyka.

Risks and catalysts affecting H02.SI stock

Key catalysts: dividend announcements, portfolio rebalancing by investment holders, and consumer demand for topical analgesics. Risks include a high payout ratio, slower cash flow growth (free cash flow per share S$0.68), and sector headwinds. Haw Par’s net debt is negligible and cash per share is S$3.77, which cushions downside but does not eliminate earnings or demand risks.

Final Thoughts

The pre-market volume spike in H02.SI stock on 21 Mar 2026 — 508,300 shares vs average 317,276 — flags higher near-term interest. Valuation is attractive: PE 13.25 and PB 0.82 against Healthcare peers. Dividend yield of 8.80% is notable but comes with a payout ratio above 100%, which raises sustainability questions. Meyka AI’s forecast model projects S$20.09 in one year, implying ~30.52% upside from S$15.39; this projection is model-based and not a guarantee. For traders using the volume spike strategy, confirm direction with intraday volume sustaining above average and price clearing S$16.29. We use Meyka AI as an AI-powered market analysis platform to combine volume, fundamentals and technicals for real-time signals, but investors should weigh dividend sustainability and sector trends before adjusting exposure.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.